Syncona Proposed To Acquire All Remaining Shares Of Freeline Therapeutics It Does Not Own For $5.00/ADS
Portfolio Pulse from Charles Gross
Syncona has proposed to acquire all remaining shares of Freeline Therapeutics that it does not already own for $5.00 per ADS.
October 18, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Freeline Therapeutics' remaining shares are proposed to be acquired by Syncona for $5.00 per ADS.
The acquisition proposal by Syncona to buy all remaining shares of Freeline Therapeutics at $5.00 per ADS could potentially increase the stock price of FRLN in the short term as it indicates a positive valuation of the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100